

[freedom.information@wvt.nhs.uk](mailto:freedom.information@wvt.nhs.uk)

3 March 2020

Dear Mr Mercure,

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST FOI2019/0591**

Thank you for your request for information.

Wye Valley NHS Trust responds:

**//////////REQUEST**

**Question 1**

	<b>Rheumatology</b>	<b>Dermatology</b>	<b>Gastroenterology</b>
Is the branded biosimilar AMGEVITA listed on your formulary?	<b>Yes – if patient cannot tolerate citrate component of other bio-similar</b>	<b>Yes – if patient cannot tolerate citrate component of other bio-similar</b>	<b>Yes – if patient cannot tolerate citrate component of other bio-similar</b>

**Question 2** Under section 12 of the Freedom of Information Act 2000 this is not possible to answer due to the time taken to compile the information exceeding the time limit for answering the request as guided by the Information Commissioner's Office (ICO). This is due to the way that information is recorded. Because of this it is not possible to suggest how the question could be altered to allow information to be returned that could be collected within the ICO time limit.

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

<b>Product/place in the adalimumab therapy pathway*</b>	<b>Rheumatology</b>	<b>Dermatology</b>	<b>Gastroenterology</b>
AMGEVITA first-line	<b>Not used</b>	<b>Not used</b>	<b>Not used</b>
AMGEVITA second-line	<b>Not used</b>	<b>Not used</b>	<b>Not used</b>
HUMIRA first-line	<b>See above exemption.</b>		
HUMIRA second-line	<b>See above exemption.</b>		
HYRIMOZ first-line	<b>See above exemption.</b>		
IMRALDI first-line	<b>Not used</b>	<b>Not used</b>	<b>Not used</b>

\*How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis

patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

### Question 3

Please complete the table below:

Question	Department					
	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic arthritis	Rheumatoid arthritis	Ankylosing spondylitis	Crohn's disease	Ulcerative colitis
Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?	<b>No. NICE / ECCO / BSG guidelines followed.</b>	<b>No. NICE / ECCO / BSG guidelines followed.</b>	<b>No. NICE / ECCO / BSG guidelines followed.</b>	<b>No. NICE / ECCO / BSG guidelines followed.</b>	<b>No. NICE / ECCO / BSG guidelines followed.</b>	<b>No. NICE / ECCO / BSG guidelines followed.</b>
Are there occasions where patients can receive adalimumab outside of NICE/SMC/AWMSG/National criteria?	<b>Yes, if an IPFR application is successful</b>	<b>Yes, if an IPFR application is successful</b>	<b>Yes, if an IPFR application is successful</b>	<b>Yes, if an IPFR application is successful</b>	<b>Yes, if an IPFR application is successful</b>	<b>Yes, if an IPFR application is successful</b>

### Question 4

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?

Contractual agreement	Yes/No
Block contracts	
Fixed price on a patient-by-patient basis	Yes

**Please note that a record of previous Trust FOI responses is now available to consult online by visiting:**

<https://www.wyevalley.nhs.uk/about-us/information-requests/freedom-of-information-requests.aspx>

If you have queries or any concerns contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to:

Information Governance/Privacy Officer  
 Wye Valley NHS Trust  
 Monkmoor Court  
 31-34 Commercial Road  
 Hereford  
 HR1 2DX  
 Email: [freedom.information@wvt.nhs.uk](mailto:freedom.information@wvt.nhs.uk)

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Information Commissioner's Office  
 Wycliffe House,

Water Lane,  
Wilmslow,  
Cheshire, SK9 5AF

Telephone: 0303 123 1113 [www.ico.gov.uk](http://www.ico.gov.uk)

Yours sincerely,

Freedom of Information Coordinator

#### **Re-Use of Public Sector Information**

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value. Further information can be found at [www.opsi.gov.uk](http://www.opsi.gov.uk) where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at [www.opsi.gov.uk/advice/psi-regulations/index.htm](http://www.opsi.gov.uk/advice/psi-regulations/index.htm)